Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →